BioSpace News Archive

M6P Therapeutics , a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today a poster presentation on mucolipidosis type II at the American Society of Gene & Cell Therapy’s (ASGCT) 24 th Annual Meeting: May 11-14, 2021.

Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion TEL AVIV, Israel--( BUSINESS WIRE )-- Teva Pha

Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE) will be presented at the following upcoming medical conferences: Conference: Society for Investigative Dermatology (SID) 2021 Virtual Meeting

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for OTO-825 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 13, 2021.

Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream Additional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks. Anticipated study on track to begin in 3Q 2021

The South Carolina Hospital Association is celebrating the centennial of its founding with a campaign dedicated to the state’s healthcare workforce.

Today, The Get the Medications Right™ (GTMRx) Institute, a catalyst for change that brings critical stakeholders together who are bound by the urgent need to get the medications right, is unveiling the GTMRx Employer Toolkit.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited (“Takeda”) as a treatment for the rare genetic liver disease

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced that it plans to release its first quarter 2021 financial results after the market closes on Wednesday, May 12, 2021.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its first quarter 2021 financial results and corporate update for Wednesday, May 5, 2021.